GH Research (GHRS) Income from Non-Controlling Interests (2020 - 2025)
GH Research's (GHRS) quarterly Income from Non-Controlling Interests came in at -$14.1 million in Q3 2025, down 247.29% year-on-year from $9.6 million in Q3 2024, and down 258.36% quarter-over-quarter from $8.9 million in Q2 2025.
GH Research (GHRS) Income from Non-Controlling Interests (2020 - 2025) Analysis & Trends
GH Research's Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at -$14.1 million for Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | - |
| 10 | GH Research | 1.68 Bn | 1.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -14.12 Mn |
| Jun 30, 2025 | 8.91 Mn |
| Mar 31, 2025 | -10.22 Mn |
| Sep 30, 2024 | 9.58 Mn |
| Jun 30, 2024 | 10.93 Mn |
| Mar 31, 2024 | 9.50 Mn |
| Sep 30, 2023 | -7.86 Mn |
| Jun 30, 2023 | 9.30 Mn |
| Mar 31, 2023 | 8.54 Mn |
| Sep 30, 2022 | 6.91 Mn |
| Jun 30, 2022 | 6.72 Mn |
| Mar 31, 2022 | -8.02 Mn |
| Sep 30, 2021 | -4.68 Mn |
| Jun 30, 2021 | -2.61 Mn |
| Mar 31, 2021 | -1.35 Mn |
| Sep 30, 2020 | -45,000.00 |